LONA
LeonaBio, Inc.
$8.35
-1.65%
$78.4M
No data for this timeframe.
Vol
Market Cap$78.4M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders12 funds
Inst. Value$4.3M
Inst. Activity2 buys / 0 sells
Insider Activity0B / 4S
Insider Net $-$49.1K
SEC Reports4
Press Releases2
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·CIK 0001620463·Prev Close $8.49
Recent Activity
May 27, 2026
other
LeonaBio to Participate in Upcoming Medical and Industry Meetings in June
<p>BOTHELL, Wash., May 27, 2026 (GLOBE NEWSWIRE) -- <strong>LeonaBio, Inc.</strong> (NASDAQ: LONA)
May 11, 2026
SEC
LeonaBio, Inc. filed a DEFA14A (additional definitive proxy soliciting materials) providing notice of its 2026 Annual Me
DEFA14A — Impact 2/10
May 8, 2026
SEC
Natalie C. Holles filed an initial statement of beneficial ownership (Form 3) with the SEC, indicating her status as an
3 — Impact 2/10
May 5, 2026
Insider
Holles Natalie C. was granted 56,000 shares
Director
May 5, 2026
Insider
Silverman Peter B. was granted 56,000 shares
Director
May 5, 2026
Insider
Callori Fred was granted 56,000 shares
Director
Mar 6, 2026
SEC
LeonaBio's entire C-suite — including the CEO, CFO, CMO, and CSO — sold shares in the open market on March 4, 2026, imme
CLUSTER — Impact 3/10
Inst.
BlackRock, Inc. — ADD
56,051 shares ($576.2K)
Price Targets
$18.00
+115.6% upside
Strong Buy
Current $8.35
Low $16.00
Median $18.00
High $20.00
2 analysts
$16.00
$20.00
Analyst Ratings
2Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 27, 2026 | Piper Sandler | INITIATE | Overweight |
| Feb 19, 2026 | Mizuho | UPGRADE | Neutral → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.36 ▲ +47.3% | $-1.90 — $-0.88 | 25% YoY | 3 |
| Next Q | $-0.71 ▲ +70.2% | $-0.91 — $-0.57 | 58% YoY | 3 |
| Current FY | $-3.12 ▲ +37.8% | $-4.35 — $-1.87 | 87% YoY | 3 |
| Next FY | $-1.79 ▲ +22.7% | $-2.68 — $-1.21 | 43% YoY | 3 |
Latest Reports
NEUTRAL
DEFA14A
2/10
LeonaBio, Inc. filed a DEFA14A (additional definitive proxy soliciting materials) providing notice of its 2026 Annual Me
May 11, 2026
NEUTRAL
3
2/10
Natalie C. Holles filed an initial statement of beneficial ownership (Form 3) with the SEC, indicating her status as an
May 8, 2026
BULLISH
Press
7/10
LeonaBio announced a virtual Key Opinion Leader event featuring two prominent breast cancer experts to discuss the poten
Apr 23, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $2.0M | — |
| RENAISSANCE TECHNOLOGIES LLC | $660.2K | ADD |
| BlackRock, Inc. | $576.2K | ADD |
| VANGUARD FIDUCIARY TRUST CO | $411.6K | — |
| BANK OF AMERICA CORP | $334.8K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 5, 2026 | Holles Natalie | A | $0.00 |
| May 5, 2026 | Silverman Peter | A | $0.00 |
| May 5, 2026 | Callori Fred | A | $0.00 |
| Apr 9, 2026 | EDELMAN JOSEPH | A | $0.00 |
| Apr 9, 2026 | JOHNSON JAMES | A | $0.00 |
12 institutional holders with $4.3M total value (421,306 shares) as of 2026-Q1. Top holders: VANGUARD, RENAISSANCE, BlackRock,. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 194,760 | $2.0M | 46.2% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 64,222 | $660.2K | 15.2% | ADD +44.7% |
| 3 | BlackRock, Inc. | 56,051 | $576.2K | 13.3% | ADD +48.9% |
| 4 | VANGUARD FIDUCIARY TRUST CO | 40,039 | $411.6K | 9.5% | — |
| 5 | BANK OF AMERICA CORP /DE/ | 32,566 | $334.8K | 7.7% | — |
| 6 | STATE STREET CORP | 16,337 | $167.9K | 3.9% | ADD +52.2% |
| 7 | TWO SIGMA INVESTMENTS, LP | 13,276 | $136.5K | 3.2% | — |
| 8 | ROYAL BANK OF CANADA | 2,225 | $23.0K | 0.5% | — |
| 9 | Vanguard Global Advisers, LLC | 1,325 | $13.6K | 0.3% | — |
| 10 | MORGAN STANLEY | 471 | $4.8K | 0.1% | — |
| 11 | JONES FINANCIAL COMPANIES LLLP | 33 | $296.00 | 0.0% | — |
| 12 | CITIGROUP INC | 1 | $10.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | ADD | 37,643 | 56,051 | +48.9% | $576.2K | 2026-Q1 |
| STATE STREET CORP | ADD | 10,737 | 16,337 | +52.2% | $167.9K | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 51,924 | 75,147 | +44.7% | $568.9K | 2025-Q4 |
15 unique insiders with 23 transactions. Net insider value: -$49.1K ($0.00 bought, $49.1K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 5, 2026 | Holles Natalie C. | Director | AWARD | 56,000 | — | — |
| May 5, 2026 | Silverman Peter B. | Director | AWARD | 56,000 | — | — |
| May 5, 2026 | Callori Fred | Director | AWARD | 56,000 | — | — |
| Apr 9, 2026 | EDELMAN JOSEPH | Director | AWARD | 28,000 | — | — |
| Apr 9, 2026 | JOHNSON JAMES A | Director | AWARD | 28,000 | — | — |
| Apr 9, 2026 | Romano Kelly A | Director | AWARD | 28,000 | — | — |
| Apr 9, 2026 | Litton Mark James | PRESIDENT and CEO | AWARD | 750,000 | — | — |
| Apr 9, 2026 | Worthington Mark | GENERAL COUNSEL and CCO | AWARD | 300,000 | — | — |
| Apr 9, 2026 | FLUKE JOHN M JR | Director | AWARD | 28,000 | — | — |
| Apr 9, 2026 | San Martin Javier | CHIEF MEDICAL OFFICER | AWARD | 350,000 | — | — |
| Apr 9, 2026 | Renninger Robert | CHIEF FINANCIAL OFFICER | AWARD | 300,000 | — | — |
| Apr 9, 2026 | PICKERING GRANT | Director | AWARD | 28,000 | — | — |
| Apr 9, 2026 | Kosacz Barbara | Director | AWARD | 28,000 | — | — |
| Apr 9, 2026 | CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | AWARD | 300,000 | — | — |
| Apr 9, 2026 | Panzara Michael A. | Director | AWARD | 28,000 | — | — |
| Mar 4, 2026 | Litton Mark James | PRESIDENT and CEO | SELL | 5,156 | $5.37 | $27.7K |
| Mar 4, 2026 | Renninger Robert | CHIEF FINANCIAL OFFICER | SELL | 906 | $5.37 | $4.9K |
| Mar 4, 2026 | CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | SELL | 1,359 | $5.37 | $7.3K |
| Mar 4, 2026 | San Martin Javier | CHIEF MEDICAL OFFICER | SELL | 1,720 | $5.37 | $9.2K |
| Mar 3, 2026 | Litton Mark James | PRESIDENT and CEO | EXERCISE | 22,254 | — | — |
| Mar 3, 2026 | San Martin Javier | CHIEF MEDICAL OFFICER | EXERCISE | 7,418 | — | — |
| Mar 3, 2026 | Renninger Robert | CHIEF FINANCIAL OFFICER | EXERCISE | 3,900 | — | — |
| Mar 3, 2026 | CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | EXERCISE | 5,856 | — | — |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 2.5/10.
NEUTRAL
DEFA14A
2/10
LeonaBio, Inc. filed a DEFA14A (additional definitive proxy soliciting materials) providing notice o
May 11, 2026
NEUTRAL
3
2/10
Natalie C. Holles filed an initial statement of beneficial ownership (Form 3) with the SEC, indicati
May 8, 2026
NEUTRAL
CLUSTER
3/10
LeonaBio's entire C-suite — including the CEO, CFO, CMO, and CSO — sold shares in the open market on
Mar 6, 2026
NEUTRAL
CLUSTER
3/10
Three C-suite executives at LeonaBio — the Chief Scientific Officer, CFO, and Chief Medical Officer
Mar 6, 2026
Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 2 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$18.00 mean target
+115.6% upside
Strong Buy (1.75)
$16.00 Low
$20.00 High
| Metric | Value |
|---|---|
| Current Price | $8.35 |
| Target Low | $16.00 |
| Target Mean | $18.00 |
| Target Median | $18.00 |
| Target High | $20.00 |
| # Analysts | 2 |
| Recommendation | Strong Buy (1.75) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.36 | $-1.90 | $-0.88 | 24.6% | +47.3% | — | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.71 | $-0.91 | $-0.57 | 57.7% | +70.2% | — | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-3.12 | $-4.35 | $-1.87 | 87.4% | +37.8% | 1↑ 1↓ | $0.0B | 0.0% | 3 |
| Next FY 2027-12-31 |
$-1.79 | $-2.68 | $-1.21 | 42.6% | +22.7% | 1↑ 1↓ | $0.0B | 0.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.357 | |
| 7d ago | $-1.085 | -0.272 |
| 30d ago | $-2.575 | +1.218 |
| 60d ago | $-1.955 | +0.598 |
| 90d ago | $-2.890 | +1.533 |
2 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 27, 2026 | Piper Sandler | INITIATE | — | Overweight |
| Feb 19, 2026 | Mizuho | UPGRADE | Neutral | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Apr 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Mar 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Feb 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Jan 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 27, 2026
other
LeonaBio to Participate in Upcoming Medical and Industry Meetings in June
<p>BOTHELL, Wash., May 27, 2026 (GLOBE NEWSWIRE) -- <strong>LeonaBio, Inc.</strong> (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedic
May 7, 2026
other
LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.
LeonaBio, Inc. (NASDAQ: LONA), announced the appointment of Fred Callori, J.D., Natalie Holles, and Peter Silverman, J.D. to its Board of Directors.
May 7, 2026
earnings_calendar
LONA Q1 2026 Earnings Scheduled — 2026-05-07
Apr 23, 2026
fda
LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer
<p align="center"><em>Management to be Joined by Two Clinical Leaders in the Breast Cancer Field </em></p>
Mar 26, 2026
earnings
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update
<p align="center"><em>Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential
Mar 19, 2026
earnings_calendar
LONA Q4 2025 Earnings After Market Close — 2026-03-19
Mar 2, 2026
earnings_calendar
LONA Q4 2025 Earnings After Market Close — 2026-03-02